Thallion Pharmaceuticals Inc. (TSX: TLN) is a biotechnology company focused on developing a novel treatment for Shiga Toxin producing E coli infections.

Events and Related News

›› more

News

January 9, 2012

THALLION AND LFB COMPLETE PATIENT ENROLLMENT OF PHASE II SHIGATEC TRIAL

October 24, 2011

BLINDED RESULTS FROM LOW DOSE COHORT OF PHASE II SHIGATEC TRIAL PRESENTED AT IDSA ANNUAL MEETING

October 11, 2011

THALLION ANNOUNCES 2011 THIRD QUARTER RESULTS

›› archives